Bio-Works reports second quarter 2026

For Q2 2026, net sales rose 53% to 20.0 MSEK (from 13.1 MSEK), but operating profit remained negative at -3.1 MSEK vs -7.6 MSEK and profit was -2.5 MSEK vs -7.3 MSEK. Cash flow from operating activities deteriorated to -10.9 MSEK (from -3.1 MSEK). Order intake fell to 8.9 MSEK (from 27.3 MSEK), down 18.4 MSEK, suggesting weakening demand despite revenue growth.

Analysis

The key signal is not the top-line growth; it is the gap between reported sales momentum and deteriorating cash conversion. When operating cash flow moves further negative while profits improve, it usually means working capital is absorbing the apparent earnings recovery, which is common in low-quality growth phases and often precedes a reset if collections normalize or inventory/work-in-progress unwinds.

The sharper issue is the order intake decline versus the recent revenue run-rate. That creates a near-term air pocket: even if the next quarter prints another respectable sales number, the pipeline math likely gets harder 1-2 quarters out unless management can show a faster booking cadence or a larger installed-base/recurring mix. For competitors, this is a classic window where stronger balance-sheet peers can take share on pricing or delivery terms while the weaker name has to fund growth with internal cash it does not have.

Contrarianly, the market may over-penalize the order weakness if the business is lumpy and the quarter captured timing noise rather than demand destruction. The thesis is falsified if management can show book-to-bill back above 1.0, operating cash flow improving faster than earnings, and a stable backlog/lead time profile in the next release. Until then, the burden of proof is on sustained bookings, not headline sales.

Key Decisions for Investors

• No immediate long: wait for the next quarter and require order intake to reaccelerate above the revenue run-rate before paying up for the name.
• If the stock is liquid, use a relative-value short against a stronger peer in the same end-market with better cash conversion; the cleaner balance sheet should outperform if bookings remain weak over the next 1-3 months.
• Set a hard alert on operating cash flow: if cash burn worsens again despite higher sales, treat the business as a financing-risk story and avoid holding through the next print.
• If management confirms the order decline was timing-related and backlog stays intact, consider a tactical long only on post-earnings weakness; upside would come from multiple re-rating on quality, not from near-term earnings power.